Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
- 953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies
- Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment
- Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023
A total of 953 Alzheimer’s patients are now enrolled across Cassava Sciences’ Phase 3 studies. For each Phase 3 study, patient enrollment has passed the halfway mark of the target patient enrollment. The enrollment target for both (not each) Phase 3 clinical studies is approximately 1,750 patients with mild-to-moderate Alzheimer’s disease who also meet other study eligibility criteria. There are no interim analyses in Cassava Sciences’ Phase 3 studies.
“We anticipate the completion of patient enrollment for both of our Phase 3 studies by year-end 2023,” said
Phase 3 Program with Simufilam
For detailed information regarding Cassava Sciences’ Phase 3 clinical studies, please visit: https://clinicaltrials.gov/ct2/results?term=simufilam&recrs=a&age_v=&gndr=&type=&rslt=&Search=Apply
Simufilam is Cassava Sciences’ proprietary, small molecule (oral) drug candidate that restores the normal shape and function of altered filamin A (FLNA) protein in the brain.
For More Information Contact:
(512) 501-2450, or eschoen@CassavaSciences.com
Cautionary Note Regarding Forward-Looking Statements:
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our current expectations regarding numerical targets for enrolling patients in our Phase 3 studies; our expectations for the completion of patient enrollment for both of our Phase 3 studies by year-end 2023; current enrollment trends in our Phase 3 studies; comments made by our employees regarding simufilam, our on-going Phase 3 studies and the treatment of Alzheimer’s disease; and potential benefits, if any, of our product candidates. These statements may be identified by words such as “may,” “anticipate,” “believe,” “could,” “expect,” “would”, “forecast,” “intend,” “plan,” “possible,” “potential,” and other words and terms of similar meaning.
Drug development involves a high degree of risk, and only a small number of research and development programs result in regulatory approval and commercialization of a product. Our interim data and analyses should not be relied upon as predictive of full study results for any of our studies. Our clinical results from earlier-stage clinical trials may not be indicative of full study results, or results from later-stage, or larger scale clinical trials, and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, the severity and duration of health care precautions given the COVID-19 pandemic, any unanticipated impacts of the pandemic on our business operations, and including those described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended
For further information regarding these and other risks related to our business, investors should consult our filings with the
Source: Cassava Sciences, Inc.